IGKV1D-22 and atherosclerosis: Key therapeutic strategies include: RAGE Receptor Antagonists: Agents such as FPS-ZM1 reduce atherosclerosis and inflammatory responses by blocking the binding of S100A8/A9 to RAGE, thereby inhibiting NF-κB and MAPK pathways and reducing inflammatory cell infiltration and plaque formation (33).